文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

大B细胞淋巴瘤中CAR-T细胞产品的免疫重建动力学及其对预后的影响

Dynamics of Immune Reconstitution and Impact on Outcomes across CAR-T Cell Products in Large B-cell Lymphoma.

作者信息

Luan Danny, DeWolf Susan, Fei Teng, Raj Sandeep, Shah Gunjan L, Lareau Caleb A, Alhomoud Mohammad, Salles Gilles, Rivas-Delgado Alfredo, Rejeski Kai, Park Jae H, Luttwak Efrat, Luna de Abia Alejandro, Corona Magdalena, Ntrivalas Evangelos, Cassanello Giulio, Gomez-Llobell Marina, Parascondola Allison, Scordo Michael, Hsu Katharine C, Palomba M Lia, Perales Miguel-Angel, Shouval Roni

机构信息

Department of Medicine, Weill Cornell Medicine, New York, New York.

Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, New York.

出版信息

Blood Cancer Discov. 2025 Mar 4;6(2):119-130. doi: 10.1158/2643-3230.BCD-24-0163.

DOI:10.1158/2643-3230.BCD-24-0163
PMID:39666878
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11876948/
Abstract

This study reveals differences in IR patterns after CAR-T therapy in patients with large B-cell lymphoma, with early NK cell recovery emerging as a key predictor of survival. These findings provide potential future avenues of research for improving patient outcomes and tailoring post-therapy management strategies to mitigate relapse risk.

摘要

本研究揭示了大B细胞淋巴瘤患者接受CAR-T治疗后免疫重建模式的差异，早期自然杀伤细胞恢复是生存的关键预测指标。这些发现为未来改善患者预后以及制定治疗后管理策略以降低复发风险提供了潜在的研究途径。

相似文献

[1]
Dynamics of Immune Reconstitution and Impact on Outcomes across CAR-T Cell Products in Large B-cell Lymphoma.

Blood Cancer Discov. 2025-3-4

[2]
Outcomes with bridging radiation therapy prior to chimeric antigen receptor T-cell therapy in patients with aggressive large B-cell lymphomas.

Front Immunol. 2025-1-31

[3]
Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma.

Cochrane Database Syst Rev. 2021-9-13

[4]
Real-World Analysis of Barriers to Timely Administration of Chimeric Antigen Receptor T Cell (CAR T) Therapy in Diffuse Large B-cell Lymphoma.

Transplant Cell Ther. 2024-11

[5]
A real-world comparison of commercial-use axicabtagene ciloleucel and lisocabtagene maraleucel in large B-cell lymphoma.

Blood Adv. 2025-2-11

[6]
Comparison of axicabtagene ciloleucel and tisagenlecleucel patient CAR-T cell products by single-cell RNA sequencing.

J Immunother Cancer. 2025-7-28

[7]
Anti-CD19 CAR-T Cell Therapy in Elderly Patients: Multicentric Real-World Experience from GETH-TC/GELTAMO.

Transplant Cell Ther. 2024-10

[8]
Comparative Efficacy of Bendamustine Versus Fludarabine/Cyclophosphamide for Lymphodepletion Before Chimeric Antigen Receptor T-Cell Therapy in Lymphoma.

Transplant Cell Ther. 2025-8

[9]
Axicabtagene Ciloleucel versus Tisagenlecleucel for Relapsed or Refractory Large B Cell Lymphoma: A Systematic Review and Meta-Analysis.

Transplant Cell Ther. 2024-6

[10]
Enrichment of CD7CXCR3 CAR T-cells in infusion products is associated with durable remission in relapsed or refractory diffuse large B-cell lymphoma.

Ann Oncol. 2025-7

引用本文的文献

[1]
Humoral vaccine responses following Chimeric Antigen Receptor T-cell therapy for hematological malignancies.

Blood Cancer J. 2025-7-2

[2]
Concomitant group A Streptococcus and disseminated mpox infection mimicking relapsed diffuse large B-cell lymphoma.

JAAD Case Rep. 2025-4-26

本文引用的文献

[1]
Immune effector cell-associated haematotoxicity after CAR T-cell therapy: from mechanism to management.

Lancet Haematol. 2024-6

[2]
CD19 CAR T-Cell Therapy in Autoimmune Disease - A Case Series with Follow-up.

N Engl J Med. 2024-2-22

[3]
Breakthrough of solid tumor treatment: CAR-NK immunotherapy.

Cell Death Discov. 2024-1-20

[4]
CAR-T cell manufacturing: Major process parameters and next-generation strategies.

J Exp Med. 2024-2-5

[5]
Lymphodepletion - an essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle.

Front Immunol. 2023

[6]
Infections after chimeric antigen receptor (CAR)-T-cell therapy for hematologic malignancies.

Transpl Infect Dis. 2023-11

[7]
Mesothelin-targeting T cell receptor fusion construct cell therapy in refractory solid tumors: phase 1/2 trial interim results.

Nat Med. 2023-8

[8]
CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results.

Nat Med. 2023-7

[9]
Negative Prognostic Impact of High-Dose or Long-Term Corticosteroid Use in Patients with Relapsed or Refractory B-Cell Lymphoma Who Received Tisagenlecleucel.

Transplant Cell Ther. 2023-9

[10]
Long-term outcomes following CAR T cell therapy: what we know so far.

Nat Rev Clin Oncol. 2023-6

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索